Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
Fandifi Technology Corp. (CSE: FDM) (OTC: FDMSF) Fandifi is a crowd-based and system-generated prediction fan engagement platform. The platform runs on an associated neural network tailor-made for content creators to increase the gamification of their content and enable fan engagement within their communities regardless of the form of distribution. FandifiTM also operates www.fandomart.com, an NFT marketplace where rewards can be bought, sold, or traded on a blockchain-agnostic platform.
Recently the market has been volatile, primarily to the downside. And small stocks have been understandably pummelled. One way of putting a positive spin, and actually a proper spin, is that if you liked them, you should enjoy them now. Or maybe pick up a few shares to average down or provide a low-cost entry. The growth is there and coming.
Let’s Beta
The latest news from FDM is the opening of beta testing with Elite Duels players;
David Vinokurov, Fandifi CEO and President states, “We’re excited to activate our partner campaign with Elite Duels, which has built up a solid reputation as a fantasy esports operator over their past several years of operation. Our campaign aims to leverage the tools and resources we have deployed to share our story with highly engaged Esports fans. We’re looking forward to expanding our partner outreach promotions beyond Elite Duels with additional partners as our marketing program unfolds.’
This partnership is deep as Elite Duels brings the fun and excitement from fantasy sports to Esports. Elite Duels offers over 10 different Esport titles, where users can compete in daily, weekly, and exclusive event fantasy contests for in-game prizes, which offers over 10 other Esport titles, where its large user base competes daily, weekly, and full event fantasy contests for in-game rewards.
Not sure what a Beta program is? ‘Beta’ is a standard term to denote a milestone release during production in which game functionality is included and optimized (but may have bugs), game content is finished (but may have some implementation errors), and is considered nearly complete. Beta represents the sum total of what the game will be, and content or functionality changes beyond beta are usually considered outside the framework of a publishing contract (called ‘change control’). Online publishers often release beta software to the public as an ‘open beta .’Open betas invite customers to play the game, report any issues that they find and participate in the community surrounding the game ahead of launch. Available betas are also often a great way to engage players with a marketing story early on.
Signups for Fandifi’s Beta commenced on September 29, 2022. Players of the Fandifi platform can sign up on the Company’s signup page at Fandifi.com. The companies have also agreed to a joint marketing effort, which is never bad.
A friend of mine, who is almost 40, games regularly. He has contacts worldwide with whom he has gamed for years. More than a social outlet, it opens up his horizons to other cultures and a kind of global ‘What Up?’
For those investors who wish to dig deeper, access FDM’s Corporate Presentation.
And more…
1. https://financesonline.com/gamification-statistics/
2. Gamification analytics tracks the user’s behaviour with the game system, helps game managers and administrators understand how the game is used by the employees and delivers valuable insights into user behaviours. tracks the user’s behaviour with the game system, helps game managers and administrators understand how the game is used by the employees and delivers valuable insights into user behaviours.
3. Fandifi Opportunity: Fandifi provides a unique agnostic platform that allows content creators to engage with their fans with a unique system to incentivize those fans to engage with their full stream through Fandifi’s unique enterprise prediction engine. The addressable market for Fandifi is in the Billions of viewers and millions of content creators. Fandifi is uniquely positioned to change how people interact with streamed and broadcast content around the world.
4. Fox News Interview (click and scroll down) with CEO Vinokurov.
Fandifi is no one tech (See how I did that?) pony. The progress is impressive, and the potential is compelling. For risk-oriented investors or those who like to buy skookum tech stocks at low prices, give Fandifi a peak.
©2024 10xAlerts